ACE2 and viral infectious disease: The second is a biological therapeutic method related to the inhibition of viral infection in host cells, including SARS-CoV-2 S protein-neutralizing antibody, recombinant human soluble ACE2 protein, and new biological products designed against the key checkpoints in the life cycle of SARS-CoV-28–10.